💰 MeiraGTx buys back eye gene therapy from J&J for just $25M: The gene therapy, known as bota-vec, failed a Phase 3 study for X-linked retinitis pigmentosa (XLRP) last year. But physicians and patient advocates …
Cochrane review dismissing amyloid drugs draws immediate backlash
A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins


